Literature DB >> 1911453

Clinical relevance of biochemical modulation of 5-fluorouracil.

G J Peters1, C J van Groeningen.   

Abstract

Biochemical modulation is a special type of combination chemotherapy which aims to selectively improve the therapeutic index by increasing the antitumor effect and protecting against toxic side effects. Biochemical modulation seems to be an attractive way to circumvent quantitative and qualitative heterogeneity of tumors. In the past decade a number of biochemical modulation approaches have been tested to improve the activity of 5-fluorouracil (5FU). 5FU itself has only modest anticancer activity but has been shown to be a very attractive target for biochemical modulation. A number of the combinations have been ineffective in the clinic despite extensive testing in a number of schedules. Some other combinations were initially tested in an inappropriate schedule, but were active when applied in another schedule. The latter was made possible by a systematic preclinical development of combinations with a proper translation to the clinic accompanied by pharmacodynamic evaluation. This review describes a number of biochemical modulation combinations, both inactive and active. The main conclusion is that properly applied biochemical modulation schedules may lead to successful use in the clinic.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1911453     DOI: 10.1093/oxfordjournals.annonc.a057994

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  16 in total

1.  P-glycoprotein-expressing tumor cells are resistant to anticancer drugs in human gastrointestinal cancer.

Authors:  T Hotta; H Tanimura; M Iwahashi; M Tani; T Tsunoda; K Noguchi; S Mizobata; K Arii; H Terasawa; M Nakamori; H Yamaue
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

Review 2.  Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes.

Authors:  E Masson; W C Zamboni
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

3.  Inhibition of dihydropyrimidine dehydrogenase by alpha-interferon: experimental data on human tumor cell lines.

Authors:  G Milano; J L Fischel; M C Etienne; N Renée; P Formento; A Thyss; M H Gaspard; L Thill; D Cupissol
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil.

Authors:  J A van Laar; C L van der Wilt; M Treskes; W J van der Vijgh; G J Peters
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Crystallization and preliminary X-ray diffraction analysis of Salmonella typhimurium uridine phosphorylase complexed with 5-fluorouracil.

Authors:  A A Lashkov; A G Gabdoulkhakov; A A Shtil; A M Mikhailov
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-05-22

6.  Plasma 5-fluorouracil and alpha-fluoro-beta-alanin accumulation in lung cancer patients treated with continuous infusion of cisplatin and 5-fluorouracil.

Authors:  L Thiberville; P Compagnon; N Moore; G Bastian; M O Richard; M F Hellot; C Vincent; M M Kannass; S Dominique; C Thuillez
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 7.  New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: Thymidylate synthase.

Authors:  C L van der Wilt; G J Peters
Journal:  Pharm World Sci       Date:  1994-04-15

8.  Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma.

Authors:  G J Peters; J Lankelma; R M Kok; P Noordhuis; C J van Groeningen; C L van der Wilt; S Meyer; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  Effects of 5-benzylacyclouridine, an inhibitor of uridine phosphorylase, on the pharmacokinetics of uridine in rhesus monkeys: implications for chemotherapy.

Authors:  J P Sommadossi; E M Cretton; L B Kidd; H M McClure; D C Anderson; M H el Kouni
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

10.  Biochemical consequences of 5-fluorouracil gastrointestinal toxicity in rats; effect of high-dose uridine.

Authors:  J Kralovanszky; N Prajda; S Kerpel-Fronius; T Bagrij; E Kiss; G J Peters
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.